These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects. Kato N; Kusumi T; Kamataki A; Tsunoda R; Fukase M; Kurose A Hum Pathol; 2017 Jan; 59():41-47. PubMed ID: 27664536 [TBL] [Abstract][Full Text] [Related]
3. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. de Kock L; Terzic T; McCluggage WG; Stewart CJR; Shaw P; Foulkes WD; Clarke BA Am J Surg Pathol; 2017 Sep; 41(9):1178-1187. PubMed ID: 28654427 [TBL] [Abstract][Full Text] [Related]
4. DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Schultz KAP; Harris AK; Finch M; Dehner LP; Brown JB; Gershenson DM; Young RH; Field A; Yu W; Turner J; Cost NG; Schneider DT; Stewart DR; Frazier AL; Messinger Y; Hill DA Gynecol Oncol; 2017 Dec; 147(3):521-527. PubMed ID: 29037807 [TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors. Yuan Z; Huo X; Jiang D; Yu M; Cao D; Wu H; Shen K; Yang J; Zhang Y; Zhou H; Wang Y Oncologist; 2020 Sep; 25(9):e1396-e1405. PubMed ID: 32557933 [TBL] [Abstract][Full Text] [Related]
8. Pediatric Sertoli-Leydig Cell Tumors of the Ovary: An Integrated Study of Clinicopathological Features, Pan-cancer-Targeted Next-generation Sequencing and Chromosomal Microarray Analysis From a Single Institution. Yang B; Chour W; Salazar CG; Zamiara P; Schmidt RJ; Raca G; Shillingford N; Zhou S; Warren M; Parham DM; Pawel B; Wang LL Am J Surg Pathol; 2024 Feb; 48(2):194-203. PubMed ID: 37946548 [TBL] [Abstract][Full Text] [Related]
9. DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. Karnezis AN; Wang Y; Keul J; Tessier-Cloutier B; Magrill J; Kommoss S; Senz J; Yang W; Proctor L; Schmidt D; Clement PB; Gilks CB; Huntsman DG; Kommoss F Am J Surg Pathol; 2019 May; 43(5):628-638. PubMed ID: 30986800 [TBL] [Abstract][Full Text] [Related]
10. Sertoli-Leydig cell tumor in two siblings with DICER1 syndrome: A case report and literature review. Zhang Y; Ren M; Hong Y; Zhong Y; Cong X; Chen C; Liu Z; Man Y; Yang L Medicine (Baltimore); 2020 Jul; 99(27):e20806. PubMed ID: 32629665 [TBL] [Abstract][Full Text] [Related]
11. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumours: a GINECO Group study. Goulvent T; Ray-Coquard I; Borel S; Haddad V; Devouassoux-Shisheboran M; Vacher-Lavenu MC; Pujade-Laurraine E; Savina A; Maillet D; Gillet G; Treilleux I; Rimokh R Histopathology; 2016 Jan; 68(2):279-85. PubMed ID: 26033501 [TBL] [Abstract][Full Text] [Related]
12. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs. McCluggage WG; Rivera B; Chong AS; Clarke BA; Schultz KAP; Dehner LP; Tchrakian N; Apellaniz-Ruiz M; Gilks CB; Kommoss F; Stewart CJR; Foulkes WD Am J Surg Pathol; 2023 Apr; 47(4):490-496. PubMed ID: 36583307 [TBL] [Abstract][Full Text] [Related]
13. Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of Golmard L; Vasta LM; Duflos V; Corsini C; Dubois d'Enghien C; McMaster ML; Harney LA; Carr AG; Ling A; Dijoud F; Gauthier A; Miettinen M; Cost NG; Gauthier-Villars M; Orbach D; Irtan S; Haouy S; Schultz KA; Stoppa-Lyonnet D; Coupier I; Stewart DR; Sirvent N J Med Genet; 2022 Apr; 59(4):346-350. PubMed ID: 33782093 [No Abstract] [Full Text] [Related]
14. A family with Sertoli-Leydig cell tumour, multinodular goiter, and Haley M; Bindal P; McAuliffe A; Vredenburgh J Curr Oncol; 2019 Jun; 26(3):183-185. PubMed ID: 31285663 [TBL] [Abstract][Full Text] [Related]
15. Reclassification of two germline DICER1 splicing variants leads to DICER1 syndrome diagnosis. Apellaniz-Ruiz M; Sabbaghian N; Chong AL; de Kock L; Cetinkaya S; Bayramoğlu E; Dinjens WNM; McCluggage WG; Wagner A; Yilmaz AA; Foulkes WD Fam Cancer; 2023 Oct; 22(4):487-493. PubMed ID: 37248399 [TBL] [Abstract][Full Text] [Related]
16. The co-occurrence of an ovarian Sertoli-Leydig cell tumor with a thyroid carcinoma is highly suggestive of a DICER1 syndrome. Durieux E; Descotes F; Mauduit C; Decaussin M; Guyetant S; Devouassoux-Shisheboran M Virchows Arch; 2016 May; 468(5):631-6. PubMed ID: 26983701 [TBL] [Abstract][Full Text] [Related]
17. Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries. Nelson AT; Harris AK; Watson D; Kamihara J; Chen KS; Stall JN; Devins KM; Young RH; Olson DR; Mallinger PHR; Mitchell SG; Hoffman LM; Halliday G; Suleymanova AM; Glade Bender JL; Messinger YH; Herzog CE; Field AL; Frazier AL; Stewart DR; Dehner LP; Hill DA; Billmire DF; Schneider DT; Schultz KAP Gynecol Oncol; 2024 Jul; 186():117-125. PubMed ID: 38657450 [TBL] [Abstract][Full Text] [Related]
18. Familial multinodular goiter and Sertoli-Leydig cell tumors associated with a large intragenic in-frame Apellaniz-Ruiz M; de Kock L; Sabbaghian N; Guaraldi F; Ghizzoni L; Beccuti G; Foulkes WD Eur J Endocrinol; 2018 Feb; 178(2):K11-K19. PubMed ID: 29187512 [TBL] [Abstract][Full Text] [Related]
19. [Ovarian Sertoli-Leydig cell tumors: DICER1 hotspot mutations and associated clinicopathological features]. Xiao YX; Zhu XL; Bi R; Tu XY; Cheng YF; Chang B; Yu L; Huang D; Lu YM; Shan L; Yang WT Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):441-447. PubMed ID: 32392927 [No Abstract] [Full Text] [Related]
20. Distinct somatic DICER1 hotspot mutations in three metachronous ovarian Sertoli-Leydig cell tumors in a patient with DICER1 syndrome. Garcia A; Desrosiers L; Scollon S; Gruner S; Reuther J; Gandhi I; Patil N; Fuller MY; Dai H; Muzny D; Gibbs RA; Bercaw-Pratt JL; Rao SL; Rainusso N; Fisher KE; Lin FY; Plon SE; Parsons DW; Roy A Cancer Genet; 2022 Apr; 262-263():53-56. PubMed ID: 35026696 [No Abstract] [Full Text] [Related] [Next] [New Search]